PDT has received $1.14m grant from JDRF to further develop an advanced infusion set, which combines continuous glucose monitoring (CGM) and insulin infusion into a single device.
The single-port CGM solution will allow users to track glucose concentration from the same device used to infuse insulin, enabling to avoid the wearing of a second device.
PDT has been refining prototypes in animal studies, as the firm is planning to take FDA approval to test the device in people.
The partnership will support PDT's efforts through a series of milestone payments, helping to commercially launch the product in the market.
For the development of new treatment, PDT secured around $5m through grants from JDRF, the National Institute of Diabetes and Digestive and Kidney Health, and The Leona M. and Harry B. Helmsley Charitable Trust.
JDRF research business development director Vincent Crabtree said: "JDRF is excited to partner with Pacific Diabetes Technologies to help advance infusion set technology that could improve the lives of people living with type 1 diabetes.”
PDT president and CEO Robert Cargill said: "This JDRF funding provides critical support as we move our technology into human feasibility trials and prepare our products for market.
“Partnerships like this and support from the NIH help to propel innovative life sciences ideas out of the research lab and into the hands of consumers."
JDRF collaborates with academic institutions, policymakers, and corporate and industry partners to develop and deliver a pipeline of innovative therapies to treat patients with T1D.
